Soleno Therapeutics (SLNO) Capital Expenditures (2013 - 2026)

Soleno Therapeutics (SLNO) has 12 years of Capital Expenditures data on file, last reported at $4000.0 in Q1 2026.

• On a quarterly basis, Capital Expenditures changed N/A year-over-year to $4000.0 in Q1 2026; TTM through Mar 2026 was $77000.0, a 62.8% decrease from a year earlier, with the FY2025 full-year figure at $73000.0, down 66.51% from the prior year.
• Capital Expenditures for Q1 2026 stood at $4000.0, down from $58000.0 in the prior quarter.
• Over the last five years, Capital Expenditures for SLNO reached as high as $191000.0 in Q3 2024 and fell as low as -$7000.0 in Q4 2022.
• Historically, Capital Expenditures has averaged $32000.0 across 4 years, with a median of $8000.0 in 2024.
• Across the five-year window, Capital Expenditures plunged 153.85% in 2022 and soared 625.0% in 2025, its largest moves.
• Year by year, Capital Expenditures stood at -$7000.0 in 2022, then surged by 214.29% to $8000.0 in 2024, then surged by 625.0% to $58000.0 in 2025, then sank by 93.1% to $4000.0 in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $4000.0 in Q1 2026, $58000.0 in Q4 2025, and $1000.0 in Q3 2025.